Shares of Pfizer Inc. (NYSE: PFE) gained over 5% on Wednesday following the corporate’s announcement of its first quarter 2024 earnings outcomes. Though the highest and backside line numbers decreased from the prior yr, they surpassed analysts’ projections. The pharma big additionally raised its adjusted EPS steerage for the total yr of 2024. Listed here are the important thing takeaways from the Q1 report:
Higher-than-expected outcomes
In Q1 2024, Pfizer’s web revenues decreased 20% year-over-year to $14.9 billion however got here above expectations. On an operational foundation, revenues declined 19%. The lower within the prime line was primarily as a result of a drop in world revenues of Comirnaty and Paxlovid. Excluding contributions from these two COVID merchandise, revenues elevated 11% operationally.
Reported web revenue decreased 44% to $3.1 billion, or $0.55 per share, in comparison with final yr. Adjusted EPS fell 33% YoY to $0.82, however surpassed estimates.
Enterprise efficiency
Throughout Q1, Comirnaty revenues decreased 88% operationally to $354 million, primarily as a result of decrease contractual deliveries and demand in worldwide markets, in addition to decrease US volumes, reflecting the seasonality of demand for vaccinations and the transition to conventional business market gross sales in sure markets, together with the US.
Paxlovid revenues declined 50% operationally to $2 billion, primarily as a result of decrease contractual deliveries within the US and most worldwide markets as a result of transition to conventional business market gross sales, in addition to decrease demand in China.
Through the quarter, Pfizer witnessed energy in its non-COVID product portfolio. It noticed income progress for in-line manufacturers such because the Vyndaqel household, Prevnar household, Eliquis, and Abrysvo. It additionally benefited from income contributions from legacy Seagen. This energy was partly offset by decrease revenues for Sulperazon, Ibrance, and oncology biosimilars.
Up to date outlook
Pfizer raised its adjusted EPS steerage for full yr 2024 because it stays assured in attaining its price realignment program goal and within the energy of its enterprise. The corporate now expects adjusted EPS of $2.15-2.35 versus its prior outlook of $2.05-2.25.
Its income steerage for the yr stays unchanged at $58.5-61.5 billion. This consists of anticipated revenues of approx. $5 billion for Comirnaty and $3 billion for Paxlovid, in addition to round $3.1 billion from legacy Seagen. The corporate expects 90% of Comirnaty gross sales to happen within the again half of the yr, principally within the fourth quarter, given the seasonality of demand for COVID vaccinations.
